Replies to post #277554 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Occam’s razor. If you don’t think the SAP timing has Merck’s fingerprints all over it.... whew.

Nobody else wants to be like NWBO, and yet here Merck is, sharing employees to work out combinations and SAPs.

And here the usual suspects are, feigning ignorance.

It’s not that hard, is it? Most of NWBO’s IP will run from time of approval, they’ve mercilessly created a monstrous twelve year data set, with what will be five year follow up from last patient’s surgery and/or enrollment and nobody followed them. — aka: barrier to entry.

[Horseb4CarT]

As previously established, Merck is doing a combination trial of Keytruda and DCVax-L. Wouldn’t it be desirable for DCVax to be an approved treatment in order to make the combination treatment available?